Edition:
India

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

0.24USD
2:05am IST
Change (% chg)

$-0.13 (-35.49%)
Prev Close
$0.38
Open
$0.28
Day's High
$0.28
Day's Low
$0.22
Volume
682,847
Avg. Vol
132,920
52-wk High
$3.57
52-wk Low
$0.22

Latest Key Developments (Source: Significant Developments)

Advaxis - On Dec 10 Co Received Written Notice Of Termination From Amgen With Respect To License & Collaboration Agreement, Dated As Of Aug 1, 2016
Friday, 14 Dec 2018 

Dec 13 (Reuters) - Advaxis Inc ::ADVAXIS - ON DEC 10 CO RECEIVED WRITTEN NOTICE OF TERMINATION FROM AMGEN WITH RESPECT TO LICENSE & COLLABORATION AGREEMENT, DATED AS OF AUG 1, 2016.ADVAXIS INC - TERMINATION OF AGREEMENT IS EFFECTIVE AS OF FEBRUARY 8, 2019 - SEC FILING.ADVAXIS INC - AGREEMENT IS PERTAINING TO DEVELOPMENT AND COMMERCIALIZATION OF CO'S ADXS-NEO PROGRAM.ADVAXIS - CO'S ADXS-NEO STUDY IS CURRENTLY ENROLLING PATIENTS AND CO WILL EVALUATE WHETHER TO RE-PARTNER ADXS-NEO PROGRAM.ADVAXIS -UPON TERMINATION, LICENSE TO AMGEN TO TERMINATE & CO TO REGAIN WORLDWIDE RIGHTS FOR DEVELOPMENT & COMMERCIALIZATION OF ADXS-NEO PROGRAM.  Full Article

Advaxis Reports Fiscal 2018 Q3 Loss Per Share Of $0.27
Tuesday, 11 Sep 2018 

Sept 10 (Reuters) - Advaxis Inc ::ADVAXIS REPORTS FISCAL 2018 THIRD QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.QTRLY REVENUE $1.2 MILLION VERSUS $3.1 MILLION.  Full Article

Advaxis Inc Files For Mixed Shelf Of Up To $250 Million
Friday, 24 Aug 2018 

Aug 23 (Reuters) - Advaxis Inc ::ADVAXIS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION .  Full Article

Advaxis Announces FDA Allowance Of IND Application For ADXS-Hot Drug Candidate
Monday, 30 Jul 2018 

July 30 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES FDA ALLOWANCE OF IND APPLICATION FOR ADXS-HOT DRUG CANDIDATE FOR NON-SMALL CELL LUNG CANCER.ADVAXIS INC - AFFIRMS PLANS TO SUBMIT A TOTAL OF FOUR IND FOR DRUG CANDIDATES FROM ITS ADXS-HOT PROGRAM BY Q4 OF 2019.ADVAXIS - PLANS TO INITIATE PHASE 1/2 CLINICAL TRIAL THAT WILL SEEK TO ESTABLISH SAFETY, TOLERABILITY AND EFFECTIVENESS OF ADXS-503.ADVAXIS INC - ANTICIPATES FIRST PATIENT IN PHASE 1/2 TRIAL FOR THIS NSCLC DRUG CANDIDATE WILL BE DOSED BY END OF 2018.  Full Article

Advaxis Says FDA Lifts Clinical Hold On Phase 1/2 Combination Study Of Axalimogene Filolisbac
Friday, 13 Jul 2018 

July 13 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES FDA LIFTS CLINICAL HOLD ON PHASE 1/2 COMBINATION STUDY OF AXALIMOGENE FILOLISBAC WITH DURVALUMAB.ADVAXIS INC - ENROLLMENT AND DOSING IN ALL OTHER ADVAXIS AND DURVALUMAB CLINICAL PROGRAMS WERE NOT AFFECTED BY CLINICAL HOLD.  Full Article

Advaxis Appoints Molly Henderson As Chief Financial Officer
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Advaxis Inc ::ADVAXIS APPOINTS MOLLY HENDERSON AS CHIEF FINANCIAL OFFICER.ADVAXIS INC - HENDERSON JOINS ADVAXIS FROM CEDAR CLIFF, LLC.  Full Article

Advaxis Announces Executive Leadership Changes
Monday, 23 Apr 2018 

April 23 (Reuters) - Advaxis Inc ::ADVAXIS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES.ADVAXIS INC - KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.ADVAXIS INC - INTERIM CEO ANTHONY LOMBARDO WILL REMAIN WITH ADVAXIS FOR A PERIOD OF TIME.  Full Article

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article